231 related articles for article (PubMed ID: 25809858)
1. Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors.
Nakamichi S; Nokihara H; Yamamoto N; Yamada Y; Fujiwara Y; Tamura Y; Wakui H; Honda K; Mizugaki H; Kitazono S; Tanabe Y; Asahina H; Yamazaki N; Suzuki S; Matsuoka M; Ogita Y; Tamura T
Invest New Drugs; 2015 Jun; 33(3):641-51. PubMed ID: 25809858
[TBL] [Abstract][Full Text] [Related]
2. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.
Leijen S; Middleton MR; Tresca P; Kraeber-Bodéré F; Dieras V; Scheulen ME; Gupta A; Lopez-Valverde V; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Schellens JH; Eberhardt WE
Clin Cancer Res; 2012 Sep; 18(17):4794-805. PubMed ID: 22767668
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors.
Honda K; Yamamoto N; Nokihara H; Tamura Y; Asahina H; Yamada Y; Suzuki S; Yamazaki N; Ogita Y; Tamura T
Cancer Chemother Pharmacol; 2013 Sep; 72(3):577-84. PubMed ID: 23860959
[TBL] [Abstract][Full Text] [Related]
4. Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.
Zimmer L; Barlesi F; Martinez-Garcia M; Dieras V; Schellens JH; Spano JP; Middleton MR; Calvo E; Paz-Ares L; Larkin J; Pacey S; Venturi M; Kraeber-Bodéré F; Tessier JJ; Eberhardt WE; Paques M; Guarin E; Meresse V; Soria JC
Clin Cancer Res; 2014 Aug; 20(16):4251-61. PubMed ID: 24947927
[TBL] [Abstract][Full Text] [Related]
5. Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials.
Kraeber-Bodéré F; Carlier T; Naegelen VM; Shochat E; Lumbroso J; Trampal C; Nagarajah J; Chua S; Hugonnet F; Stokkel M; Gleeson F; Tessier J
J Nucl Med; 2012 Dec; 53(12):1836-46. PubMed ID: 23143089
[TBL] [Abstract][Full Text] [Related]
6. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.
Rosen LS; LoRusso P; Ma WW; Goldman JW; Weise A; Colevas AD; Adjei A; Yazji S; Shen A; Johnston S; Hsieh HJ; Chan IT; Sikic BI
Invest New Drugs; 2016 Oct; 34(5):604-13. PubMed ID: 27424159
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study.
Saka H; Kitagawa C; Kogure Y; Takahashi Y; Fujikawa K; Sagawa T; Iwasa S; Takahashi N; Fukao T; Tchinou C; Landers D; Yamada Y
Invest New Drugs; 2017 Aug; 35(4):451-462. PubMed ID: 28070720
[TBL] [Abstract][Full Text] [Related]
8. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
Adjei AA; Cohen RB; Franklin W; Morris C; Wilson D; Molina JR; Hanson LJ; Gore L; Chow L; Leong S; Maloney L; Gordon G; Simmons H; Marlow A; Litwiler K; Brown S; Poch G; Kane K; Haney J; Eckhardt SG
J Clin Oncol; 2008 May; 26(13):2139-46. PubMed ID: 18390968
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.
Goldman JW; Rosen LS; Tolcher AW; Papadopoulos K; Beeram M; Shi P; Pitou C; Bell R; Kulanthaivel P; Zhang X; Fink A; Chan EM; Shahir A; Farrington D; Patnaik A
Invest New Drugs; 2018 Aug; 36(4):629-637. PubMed ID: 29196957
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.
Lorusso PM; Adjei AA; Varterasian M; Gadgeel S; Reid J; Mitchell DY; Hanson L; DeLuca P; Bruzek L; Piens J; Asbury P; Van Becelaere K; Herrera R; Sebolt-Leopold J; Meyer MB
J Clin Oncol; 2005 Aug; 23(23):5281-93. PubMed ID: 16009947
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose.
Venkatakrishnan K; Kim TM; Lin CC; Thye LS; Chng WJ; Ma B; Chen MH; Zhou X; Liu H; Kelly V; Kim WS
Invest New Drugs; 2015 Aug; 33(4):942-53. PubMed ID: 26084989
[TBL] [Abstract][Full Text] [Related]
12. Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Edelman G; Rodon J; Lager J; Castell C; Jiang J; Van Allen EM; Wagle N; Lindeman NI; Sholl LM; Shapiro GI
Oncologist; 2018 Apr; 23(4):401-e38. PubMed ID: 29593099
[TBL] [Abstract][Full Text] [Related]
13. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
Martinez-Garcia M; Banerji U; Albanell J; Bahleda R; Dolly S; Kraeber-Bodéré F; Rojo F; Routier E; Guarin E; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Soria JC
Clin Cancer Res; 2012 Sep; 18(17):4806-19. PubMed ID: 22761467
[TBL] [Abstract][Full Text] [Related]
14. A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors.
Shimizu T; Fukuoka K; Takeda M; Iwasa T; Yoshida T; Horobin J; Keegan M; Vaickus L; Chavan A; Padval M; Nakagawa K
Cancer Chemother Pharmacol; 2016 May; 77(5):997-1003. PubMed ID: 27025608
[TBL] [Abstract][Full Text] [Related]
15. A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.
Adjei AA; LoRusso P; Ribas A; Sosman JA; Pavlick A; Dy GK; Zhou X; Gangolli E; Kneissl M; Faucette S; Neuwirth R; Bózon V
Invest New Drugs; 2017 Feb; 35(1):47-58. PubMed ID: 27650277
[TBL] [Abstract][Full Text] [Related]
16. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers.
LoRusso PM; Krishnamurthi SS; Rinehart JJ; Nabell LM; Malburg L; Chapman PB; DePrimo SE; Bentivegna S; Wilner KD; Tan W; Ricart AD
Clin Cancer Res; 2010 Mar; 16(6):1924-37. PubMed ID: 20215549
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors.
Schöffski P; Aftimos P; Dumez H; Deleporte A; De Block K; Costermans J; Billiet M; Meeus MA; Lee C; Schnell D; Goeldner RG; Awada A
Cancer Chemother Pharmacol; 2016 Jan; 77(1):99-108. PubMed ID: 26650227
[TBL] [Abstract][Full Text] [Related]
18. Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.
Delord JP; Italiano A; Awada A; Aftimos P; Houédé N; Lebbé C; Pages C; Lesimple T; Dinulescu M; Schellens JHM; Leijen S; Rottey S; Kruse V; Kefford R; Faivre S; Gomez-Roca C; Scheuler A; Massimini G; Raymond E
Target Oncol; 2021 Jan; 16(1):37-46. PubMed ID: 33170484
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations.
Nishio M; Murakami H; Ohe Y; Hida T; Sakai H; Kasahara K; Imamura F; Baba T; Kubota K; Hosomi Y; Shimokawa T; Hayashi H; Miyadera K; Tamura T
Invest New Drugs; 2019 Dec; 37(6):1207-1217. PubMed ID: 30790152
[TBL] [Abstract][Full Text] [Related]
20. Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors.
Esaki T; Hirai F; Makiyama A; Seto T; Bando H; Naito Y; Yoh K; Ishihara K; Kakizume T; Natsume K; Myers A; Doi T
Cancer Sci; 2019 Apr; 110(4):1340-1351. PubMed ID: 30724423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
